A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis

Journal of Controlled Release

Volumn 212, Issue , 2015, Pages 59-69

  Sugahara, Kazuki N ^a,b   Scodeller, Pablo ^a   Braun, Gary B ^a,c   De Mendoza, Tatiana Hurtado ^a   Yamazaki, Chisato M ^b   Kluger, Michael D ^b   Kitayama, Joji ^d   Alvarez, Edwin ^e   Howell, Stephen B ^e   Teesalu, Tambet ^a,c,f   Ruoslahti, Erkki ^a,c   Lowy, Andrew M ^e  

^a BURNHAM INSTITUTE   (United States)

^b Herbert Irving Comprehensive Cancer Center ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f Faculty of Medicine   (Estonia)

Author keywords

integrin; intraperitoneal chemotherapy; neuropilin; peritoneal carcinomatosis; tumor penetrating peptide

Indexed keywords

CHEMOTHERAPY; MAMMALS; PATHOLOGY; PEPTIDES;

INTEGRINS; INTRAPERITONEAL; NEUROPILIN; PERITONEAL CARCINOMATOSIS; TUMOR-PENETRATING PEPTIDES;

TUMORS;

ALPHA4 INTEGRIN; CYCLOPEPTIDE; DEXTRAN; DOXORUBICIN; INTERNALIZING ARGINYLGLYCYLASPARTIC ACID; NEUROPILIN 1; PEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE; N-END CYSTEINE PEPTIDE TUMOR-HOMING PEPTIDE; OLIGOPEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER LOCALIZATION; CANCER SIZE; CARCINOMATOUS PERITONITIS; CELL SURFACE; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG UPTAKE; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SURFACE PROPERTY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; UPREGULATION; ANIMAL; BLOOD FLOW; CARCINOMA; NUDE MOUSE; PERITONEAL NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DOXORUBICIN; HUMANS; MICE, NUDE; OLIGOPEPTIDES; PERITONEAL NEOPLASMS; REGIONAL BLOOD FLOW;

EID: 84935013113     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.06.009     Document Type: Article

References (44)

1. E. Cotte, G. Passot, and F.C. Gilly Selection of patients and staging of peritoneal surface malignancies World J. Gastrointest. Oncol. 2 2010 31 35
2. A. Jemal, R. Siegel, and J. Xu Cancer Statistics, 2010 CA Cancer J. Clin. 60 2010 277 300
3. M.J. Koppe, O.C. Boerman, and W.J.G. Oyen Peritoneal carcinomatosis of colorectal origin incidence and current treatment strategies Ann. Surg. 243 2006 212 222
4. P.H. Sugarbaker New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome Lancet Oncol. 7 2006 69 76
5. D. Jayne Molecular biology of peritoneal carcinomatosis Cancer Treat. Res. 134 2007 21 33
6. E. Lengyel Ovarian cancer development and metastasis Am. J. Pathol. 177 2010 1053 1064
7. P.H. Sugarbaker, O.A. Stuart, and J. Vidal-Jove Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration Cancer Treat. Res. 82 1996 41 52
8. C.H. Heldin, K. Rubin, and K. Pietras High interstitial fluid pressure - an obstacle in cancer therapy Nat. Rev. Cancer 4 2004 806 813
9. A.I. Minchinton, and I.F. Tannock Drug penetration in solid tumours Nat. Rev. Cancer 6 2006 583 592
10. J. Choi, K. Credit, and K. Henderson Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration Clin. Cancer Res. 12 2006 1906 1912
11. A.W. El-Kareh, and T.W. Secomb A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance Neoplasia 6 2004 117 127
12. A.A. Sarnaik, J.J. Sussman, and S.A. Ahmad Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality Surg. Oncol. Clin. N. Am. 12 2003 849 863
13. A.J. Witkamp, E. de Bree, and A.R. van Goethem Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy Cancer Treat. Rev. 27 2001 365 374
14. T. Teesalu, K.N. Sugahara, and E. Ruoslahti Tumor penetrating peptides Front. Oncol. 3 2013 216
15. T. Teesalu, K.N. Sugahara, and V.R. Kotamraju C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration Proc. Natl. Acad. Sci. U. S. A. 106 2009 16157 16162
16. K.N. Sugahara, T. Teesalu, and P.P. Karmali Tissue-penetrating delivery of compounds and nanoparticles into tumors Cancer Cell 16 2009 510 520
17. J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 2010 9 22
18. E. Ruoslahti Specialization of tumour vasculature Nat. Rev. Cancer 2 2002 83 90
19. K. Kessenbrock, V. Plaks, and Z. Werb Matrix metalloproteinases: regulators of the tumor microenvironment Cell 141 2010 52 67
20. H.B. Pang, G.B. Braun, and T. Friman An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability Nat. Commun. 5 2014 4904
21. K.N. Sugahara, T. Teesalu, and P.P. Karmali Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 328 2010 1031 1035
22. C. Puig-Saus, L.A. Rojas, and E. Laborda iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy Gene Ther. 21 2014 767 774
23. K. Wang, X. Zhang, and C. Liu Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates Biomaterials 35 2014 8735 8747
24. G. Gu, X. Gao, and Q. Hu The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells Biomaterials 34 2013 5138 5148
25. Y. Akashi, T. Oda, and Y. Ohara Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1 Br. J. Cancer 110 2014 1481 1487
26. L. Agemy, D. Friedmann-Morvinski, and V.R. Kotamraju Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma Proc. Natl. Acad. Sci. U. S. A. 108 2011 17450 17455
27. G.J. Prud'homme, and Y. Glinka Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity Oncotarget 3 2012 921 939
28. R. Chen, G.B. Braun, and X. Luo Application of a proapoptotic peptide to intratumorally spreading cancer therapy Cancer Res. 73 2013 1352 1361
29. A. Koga, K. Aoyagi, and T. Imaizumi Comparison between the gastric cancer cell line MKN-45 and the high-potential peritoneal dissemination gastric cancer cell line MKN-45P Kurume Med. J. 58 2011 73 79
30. S. Emoto, H. Yamaguchi, and T. Kamei Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer Surg. Today 44 2014 919 926
31. L.D. Mayer, G. Dougherty, and T.O. Harasym The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors J. Pharmacol. Exp. Ther. 280 1997 1406 1414
32. P.H. Sugarbaker Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach Expert. Opin. Pharmacother. 10 2009 1965 1977
33. L. Alberici, L. Roth, and K.N. Sugahara De novo design of a tumor-penetrating peptide Cancer Res. 73 2013 804 812
34. M. Miyagi, K. Aoyagi, and S. Kato The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer Int. J. Clin. Oncol. 12 2007 17 24
35. O. Wilhelm, R. Hafter, and E. Coppenrath Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma Cancer Res. 48 1988 3507 3514
36. I.M. Modlin, M.D. Shapiro, and M. Kidd Carcinoid tumors and fibrosis: an association with no explanation Am. J. Gastroenterol. 99 2004 2466 2478
37. C. Hasovits, and S. Clarke Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics Clin. Pharmacokinet. 51 2012 203 224
38. J.C. Leinwand, and G.E. Bates Body surface area predicts plasma oxalliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy Ann. Surg. Oncol. 20 2013 1101 1104
39. W. Queisser, and M.E. Heim Chemotherapy in alimentary tract malignomas Hepatogastroenterology 28 1981 276 283
40. C. Cooper, C. Cooper, and R.B. Jeffrey Computed tomography of omental pathology J. Comput. Assist. Tomogr. 10 1986 62 66
41. H.A. Kenny, S. Kaur, and L.M. Coussens The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin J. Clin. Invest. 118 2008 1367 1379
42. C.O. McAtee, J.J. Barycki, and M.A. Simpson Emerging roles of hyaluronidase in cancer metastasis and therapy Adv. Cancer Res. 123 2014 1 34
43. K.N. Sugahara, G.B. Braun, and T.H. de Mendoza Tumor-penetrating iRGD peptide inhibits metastasis Mol. Cancer Ther. 14 2015 120 128
44. V.P. Torchilin Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery Nat. Rev. Drug Discov. 13 2014 813 827